靶向IL-17A驱动的PTGS2/NLRP3炎症小体活化治疗幼年型粒单核细胞白血病
该研究在Shp2E76K/+ JMML小鼠模型中发现IL-17A/PTGS2/NLRP3信号轴驱动骨髓炎症、抑制抗肿瘤免疫并促进白血病进展。联合抑制NLRP3和PTGS2可恢复细胞毒性T细胞功能、逆转骨髓增殖并显著延长生存,与MEK抑制剂联用在患者来源异种移植模型中有效减少白血病负荷。
要点
- IL-17A/PTGS2/NLRP3轴是PTPN11突变JMML免疫抑制和髓系扩增的核心驱动因素。
- 双抑制NLRP3和PTGS2联合MEK阻断可减少白血病祖细胞集落形成并延长生存。
- 该组合策略在PTPN11突变JMML患者来源异种移植模型中显示转化潜力。
核心结论
- IL-17A/PTGS2/NLRP3信号是PTPN11突变JMML免疫抑制和髓系扩增的核心驱动因素,联合抗炎靶向是有前景的治疗策略。
研究设计与样本
- 使用Shp2E76K/+ JMML小鼠模型、JMML患者原代样本体外实验及PTPN11突变JMML患者来源异种移植模型。
主要发现
- Shp2E76K/+小鼠表现为调节性T细胞扩增、T细胞耗竭增加、CD4+和CD8+ T细胞频率降低及细胞毒功能受损。
- 突变巨噬细胞上调IL-17A,触发NLRP3炎症小体活化、PTGS2诱导、caspase-1剪切和IL-1β成熟。
- IL-17A中和抑制炎症小体活性;联合抑制NLRP3和PTGS2恢复细胞毒性T细胞功能、减轻全身和骨髓炎症、逆转骨髓增殖并显著延长Shp2E76K/+小鼠生存。
- JMML患者原代样本体外双抑制NLRP3/PTGS2联合MEK阻断显著减少白血病祖细胞集落形成。
- PTPN11突变JMML患者来源异种移植模型中,双抑制NLRP3/PTGS2联合MEK阻断最有效减少白血病负荷、降低人CD45+植入、耗竭白血病CD34+CD38+祖细胞和粒-巨噬祖细胞,同时恢复巨核-红系祖细胞,显著改善总生存。
临床怎么用
- 对于PTPN11突变的高危JMML,可考虑将NLRP3/PTGS2双抑制联合MEK阻断作为潜在转化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric myelodysplastic syndrome or myeloproliferative disorder for which hematopoietic stem cell transplantation remains the only curative option; however, outcomes are particularly poor in patients harboring PTPN11 (encodes SHP2 phosphatase) mutations. Using a Shp2E76K/+ JMML mouse model, we identified a pathogenic interleukin-17A (IL-17A)/PTGS2/NLRP3 signaling axis that drives bone marrow inflammation, suppresses antitumor immunity, and promotes leukemic progression. Shp2E76K/+ mice exhibited profound immune dysregulation, characterized by expansion of regulatory T cells, increased T-cell exhaustion, and impaired cytotoxic function with reduced CD4+ and CD8+ T-cell frequencies. Mechanistically, mutant macrophages upregulated IL-17A, triggering NLRP3 inflammasome activation, PTGS2 induction, caspase-1 cleavage, and IL-1β maturation, thereby amplifying inflammatory signaling within the marrow niche. Therapeutically, IL-17A neutralization suppressed inflammasome activity, whereas the combined inhibition of NLRP3 and PTGS2 restored cytotoxic T-cell function, reduced systemic and marrow inflammation, reversed myeloproliferation, and significantly prolonged survival in Shp2E76K/+ mice. Importantly, ex vivo treatment of primary samples from patients with JMML with dual NLRP3/PTGS2 inhibition combined with mitogen-activated protein kinase kinase (MEK) blockade significantly reduced leukemic progenitor colony formation, supporting translational relevance. In patient-derived xenograft models of PTPN11-mutant JMML, dual NLRP3/PTGS2 inhibition combined with MEK blockade most effectively reduced leukemic burden, decreased human CD45+ engraftment, and depleted leukemic CD34+CD38+ progenitors and granulocyte-macrophage progenitors while restoring megakaryocyte-erythroid progenitor populations, resulting in significantly improved overall survival. Together, these findings establish IL-17A/PTGS2/NLRP3 signaling as a central driver of immune suppression and myeloid expansion in PTPN11-mutant JMML and highlight combinatorial anti-inflammatory targeting as a promising therapeutic strategy for this high-risk disease.
引用
- Pasupuleti SK, Ramdas B, Ram Padam KS, et al. Therapeutic targeting of IL-17A-driven PTGS2/NLRP3 inflammasome activation in juvenile myelomonocytic leukemia. Blood. 2026. PMID: 42233403. doi:10.1182/blood.2025032588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。